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Almost half of patients treated on intensive care unit (ICU) experience moderate to
severe pain. Managing pain in the critically ill patient is challenging, as their pain is
complex with multiple causes. Pharmacological treatment often focuses on opioids,
and over a prolonged admission this can represent high cumulative doses which risk
opioid dependence at discharge. Despite analgesia the incidence of chronic pain after
treatment on ICU is high ranging from 33–73%. Measures need to be taken to prevent
the transition from acute to chronic pain, whilst avoiding opioid overuse. This narrative
review discusses preventive measures for the development of chronic pain in ICU
patients. It considers a number of strategies that can be employed including non-
opioid analgesics, regional analgesia, and non-pharmacological methods. We reason
that individualized pain management plans should become the cornerstone for critically
ill patients to facilitate physical and psychological well being after discharge from critical
care and hospital.
Keywords: critical care, pain, chronic pain, analgesics, opioids
INTRODUCTION
The first intensive care units (ICU) were established in the United States during the 1960s, and
since this time remarkable achievements have been made in survival rates of critically ill patients
(Marini, 2015). However, prolonged periods of hospitalization in the ICU environment can impact
significantly on patients’ overall wellbeing, at discharge from both ICU and hospital (Griffiths et al.,
2013). Research regarding patient outcomes following ICU admission led to the development of the
term “post-intensive care syndrome” (PICS). This term encompasses new or worsening physical,
cognitive or mental health following a critical illness (Needham et al., 2012). This can include sleep
deprivation, fatigue, weakness and chronic pain, alone or in combination and is common following
hospital discharge after ICU treatment (Sukantarat et al., 2007; Timmers et al., 2011). It can be
accompanied by anxiety, depression, post-traumatic stress disorder (PTSD) and deterioration in
mental processing speed, memory, executive functioning and attentiveness (Sukantarat et al., 2007).
These changes can persist up to 2 years following ICU discharge (Herridge et al., 2003, 2011).
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Therefore the development of chronic pain following ICU care as
part of PICS or in isolation is an important patient outcome.
Most patients admitted to ICU receive opioids, commonly
as part of analgesia and sedation regimens. A lack of adequate
analgesia and acute pain can lead to chronic pain developing.
Whilst ensuring patient comfort and alleviating pain is an
essential aspect of patient care, the use of opioids for symptom
control may not always represent an ideal approach. Opioid
use can be associated with potential short and long term
consequences, however, their development in patients after ICU
discharge is not known. High cumulative doses or long term
opioid use within critical care could lead to opioid dependence,
tolerance, addiction, and physiological effects, such as hormone
and immune system changes (Ballantyne and Mao, 2003).
Tolerance occurs when there is a progressive decrease in the
pharmacodynamic response to the drug and can be compensated
by increasing the dose. This contrasts with dependence where
a “physical effect, abstinence syndrome is seen upon abrupt
drug withdrawal” (American Psychiatric Association, 2013).
Addiction is a chronic disease, characterized by psychological
dependence and an irreversible neurobiological disease with
compulsive drug use (American Psychiatric Association, 2013).
Opioid tolerance and/or dependence could be expected during
and after ICU admission for patients who have received high or
lengthy opioid dose regimens, however, there is little evidence
regarding the incidence of these phenomena occurring and their
impact on patients. The dichotomy then exists for critically ill
patients of either having inadequate analgesia and developing
chronic pain or having high doses of opioid analgesia and
developing consequences such as dependence or long term use.
The psychological and economical burdens of either of these
are significant to patients, their families and society in general
(Griffiths et al., 2013). It is therefore important to understand
the reasons behind commencing opioid therapy for patients
in ICU and determining whether it should continue at ICU
discharge. This article aims to consider the emerging field of
pain management within the ICU setting and outline possible
management options to minimize both chronic pain and long
term opioid use following ICU discharge.
METHODS
This narrative review aims to present the available evidence
regarding both chronic pain and opioid dependence following
ICU discharge. Additionally, it will review potential treatments
and strategies to reduce the likelihood of patients developing
chronic pain and opioid dependence following their ICU stay.
The review focuses on adult patients. The search strategy was
designed to find evidence which directly evaluated chronic
pain. The terms used alone and in combinations were “chronic
pain, critical illness,” “chronic pain, critical care,” “chronic
pain, intensive care,” “opioids, critical illness,” “analgesics,
opioids, critical care” “analgesics, non-narcotics, critical illness,”
“analgesics, non-narcotics, critical care,” “sleep deprivation,
critical illness,” “sleep deprivation, acute pain” in PubMed. The
search period was for articles between January 1989 and August
2017. Articles were written in the English language and included
those based on expert selection, open and blinded studies,
reviews, meta-analysis, commentaries and editorials, related to
the described MESH terms. From 5722 articles, we retrieved
n = 184 articles based on the above criteria. In addition to the
database search, we reviewed articles from reference sections in
relevant articles to include additional articles not found by the
original search. For analysis of chronic post ICU pain (CPIP)
and chronic opioid use after ICU, articles were excluded if they
didn’t clearly state in the methods that patients were treated in
the ICU, that included pediatric patients, that did not clearly
refer to chronic pain and chronic opioid use after ICU discharge.
Nine articles were included for analysis of chronic pain after ICU
(Granja et al., 2002; Boyle et al., 2004; Korošec Jagodicˇ et al., 2006;
Jenewein et al., 2009; Timmers et al., 2011; Battle et al., 2013;
Griffiths et al., 2013; Choi et al., 2014; Baumbach et al., 2016) and
one article for chronic opioid use (Yaffe et al., 2017).
Chronic Pain After ICU
Definition
There is no widely accepted definition of chronic pain after ICU
discharge (CPIP). Applying the definition for chronic pain used
in the ICD 11 classification for the purpose of this review, we
define chronic pain after ICU discharge as “pain persisting or
recurring 3 months” after ICU discharge (Treede et al., 2015).
There are no definitions for the type of pain (for example
nociceptive, neuropathic or visceral), encompassed by CPIP and
no studies included defined pain by type.
Incidence and Location
It is difficult to ascertain an exact incidence of CPIP. Nine
articles reported incidence that varied widely between studies
ranging from 33–73% (see Table 1). A variety of methods
were used to evaluate CPIP between studies, which could
account for these findings. Studies lacked consensus regarding
the observation period in which chronic pain was evaluated. It
ranged from 2 months to 11 years. Only one study considered
pre-existing chronic pain, an important confounding factor
(Baumbach et al., 2016). Other studies controlled for additional
confounders such as age or gender. Study designs included
comparisons to different control groups including septic vs. non-
septic patients, ICU patients with and without CPIP, and age-
and gender-matched individuals from the general population
(Jenewein et al., 2009; Timmers et al., 2011; Baumbach et al.,
2016). One study considered the bodily location of pain, which
was found in approximately a fifth of patients at the shoulder
(Battle et al., 2013).
Risk Factors
Little is known about risk factors for developing chronic pain
following ICU discharge. Five studies have attempted to explore
these (see Table 2) considering the influence of ICU admission,
ICU length of stay, duration of mechanical ventilation and
duration of sepsis on the development of CPIP. Battle et al.
(2013) identified an increased patient age and a diagnosis of
“sepsis” as risk factors for CPIP. They further identified pain
localised in the shoulder was influenced by “sepsis” and ICU
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TABLE 2 | Risk factors for chronic post ICU pain.
Primary author and year Patient population Sample size Risk factors identified
Battle 2013 Medical and surgical ICU 196 Increasing age and sepsis risk for chronic pain using multivariate analysis
Baumbach 2016 Medical and surgical ICU 207 Sepsis was not a risk factor for chronic pain
Boyle 2004 Medical and surgical ICU 52 (6 months) Chronic pain patients had longer hospital LOS and longer time of ventilation
Granja 2002 Medical and surgical ICU 275 Surgical or trauma diagnosis associated with pain/discomfort using multiple
logistic regression
Timmers 2011 Surgical ICU 575 Patient sex and trauma surgery independently associated with pain/discomfort
LOS, length of stay.
length of stay (Battle et al., 2013). However, Baumbach et al.
(2016) did not identify a diagnosis of sepsis as a risk factor
for CPIP when accounting for the presence of persistent pain
prior to ICU admission. Granja et al. (2002) found, however,
that the main diagnosis of disease at ICU admission was a
risk factor for developing pain and discomfort 6 months after
ICU discharge, with patients admitted for trauma or surgery
more likely to have CPIP. Both Timmers et al. (2011) and
Baumbach et al. (2016) did not find ICU length of stay or
days of mechanical ventilation influenced the development of
CPIP. Although CPIP was evaluated using verbal descriptors or
visual analogue scales (VAS) for pain intensity in four studies,
pain intensity was rarely considered in studies, rather presence
or absence of pain. As such, it is impossible to conclude if
acute pain intensity whilst in ICU influences the development
of CPIP (Griffiths et al., 2013; Choi et al., 2014). Therefore
there is a paucity of evidence regarding predisposing factors to
developing CPIP.
Observational data from Europe regarding the development
of chronic post surgical pain (CPSP) highlights preexisting
persistent pain as being associated with a 2.6 times higher
risk of developing CPSP (Fletcher et al., 2015). Moreover, the
percentage of time in severe pain on day one post surgery
was found to be predictive of developing CPSP (Fletcher et al.,
2015). Unfortunately there is a paucity of evidence to support
this finding with respect to CPIP, as only one study considered
this and did not identify it as an independent risk factor (Choi
et al., 2014). Kemp et al. (2017) showed that 35.5% of ICU
patients had a doctor assess pain and few used validated pain
assessment tools. If healthcare professionals fail to assess pain,
not only does this mean management may not be optimal,
but using the analogy of CPSP, untreated acute pain in ICU
could predispose to developing CPIP. Studies investigating the
connection between CPIP and pain experienced by patients
whilst in ICU are therefore needed.
Consequences of CPIP
Unsurprising, CPIP affected the physical, psychological and
social well-being of patients. CPIP was found to compromise
normal everyday living including normal work, walking,
relationships with friends and family, activity, mood and sleep
(Baumbach et al., 2016; Puntillo and Naidu, 2016). Baumbach
et al. (2016) found that 60% of patients who developed CPIP
found this moderately to severely interfered with their daily
life, family activities and work. Furthermore family members
who care for ICU survivors with moderate and severe pain
demonstrated higher distress scores themselves (Griffiths et al.,
2013). Chronic pain in general is “highly comorbid with
anxiety and depression” and whilst this might also be the
case for CPIP, no studies found this association (Katz et al.,
2015). CPIP was found to be associated with PTSD (Jenewein
et al., 2009). Whilst severe accidental injury requiring ICU
admission is likely to lead to physical disability it is notable
that in a prospective follow up study of ICU survivors who
experienced severe accidental injuries, those with CPIP had
a significantly more frequent presence of physical disability,
occupational invalidity and absence from work than those pain
free up to 3 years following their injury (Jenewein et al., 2009).
Overall these data represent the high burden CPIP places on
ICU survivors.
With the limited information available we can conclude that
the incidence of CPIP is high, however, there is conflicting
evidence supporting predisposing risk factors to its development.
Bodily localization, pain intensity and type of pain CPIP
encompasses are rarely investigated, and there was no evidence
to consider the link between pain experienced during a patients
ICU stay and the development of CPIP.
Chronic Opioid Use After ICU Discharge
Intensive care unit patients risk continuing opioids following
ICU discharge and potentially after leaving hospital due to
management of CPIP. Chou et al. (2009) adapted Von Korff
et al. (2008) definition of chronic opioid therapy as “daily or
near-daily use of opioids for at least 90 days, often indefinitely.”
One study was identified that considered opioid use following
ICU discharge. Yaffe et al. (2017) investigated opioid use
in ICU survivors with surgical and non-surgical diagnoses
by retrospectively analyzing electronic patient charts. They
identified opioid use in 12.2% of patients at hospital discharge.
This proportion fell to 4.4% when re-evaluated 48 months later.
No difference was found regarding chronic opioid use between
medical and surgical patients. There was a “discrepancy” noticed
by the authors between reported high incidence of CPIP and
low chronic opioid use. This was hypothesized to reflect non-
opioid pain management, a change in opioid prescribing for
non-cancer pain and the lack of adequate tools to define chronic
pain syndromes. However, chronic opioid use prior to ICU
admission and length of hospital stay were associated with post-
discharge chronic opioid use (Yaffe et al., 2017). The study,
however, did not evaluate consequences of long-term opioid
use or the intensity and type of pain experienced by chronic
opioid users.
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It is obvious that moderate and severe acute pain experienced
by patients in ICU requires opioid therapy; however, a balance is
required to ensure patients are comfortable throughout their ICU
admission without predisposing them to require opioids long
term after ICU discharge. Certainly, further exploration into the
incidence and consequence of chronic opioid use following ICU
admission is important especially in light of current concerns
regarding long term opioid use in general.
Preventive Measures
There is little evidence to support specific risk factors in
developing CPIP, however, preventative measures should in the
first instance be extrapolated from CPSP literature that supports
managing acute pain to reduce the risk of transition to chronic
pain states. There are few papers considering interventions
targeted at acute pain management within the ICU setting
and altered critical care outcomes. Evidence suggests, however,
that simply performing regular validated pain assessments
is associated with improved patient outcomes (Payen et al.,
2009; Skrobik et al., 2010). Below pharmacological and non-
pharmacological measures are explored that consider predicting
those at risk in the pre ICU stage, managing acute pain within
the ICU admission and management following discharge which
could reduce the transition from acute pain to CPIP.
Pre-ICU Admission: Assessment of Risk Factors
Detailed analysis of a patients’ preadmission state might play a
significant role in identifying those at risk of developing CPIP.
Patients with increasing age, and a diagnosis at ICU of trauma, or
surgery should be considered as high risk. Additionally, evidence
from CPSP suggests a more pre-emptive management strategy
including a pre-emptive analgesia model using antidepressants
or anticonvulsants early during the ICU stay could influence the
development of CPIP. Utilizing both pain focused psychological
management and physiotherapy early in ICU admission could
also reduce risk. Furthermore, a history of opioid use or
misuse prior to admission should lead to careful use of opioids
during admission.
During ICU Admission
Each patient should have an individualized pain management
plan. This should account for the leading health problem and
comorbidities, avoid medications that could deteriorate the
patients critically ill state and aim to cover pain management
throughout the patient’s ICU stay. This plan should be flexible
to account for changes in treatment and clinical condition.
The ABCDEF Bundle is an evidence based flexible framework
that is a multimodal and multidisciplinary, patient and family
centered approach for the management of the critically ill patient.
“A” within the bundle represents “Assessment, Prevention, and
Management of Pain” (Ely, 2017). This is a useful starting point
for the pain management plan.
The American College of Critical Care Medicine (ACCM)
recommends regular and meticulous assessment of pain and
sedation, followed by careful titration of opioids and sedatives
(Barr et al., 2013; Devlin et al., 2018) and prevention and
treatment of procedural pain (Barr et al., 2013). Targeting
analgesic doses to patients by using pain assessment ensures
individualized treatment and is associated with a reduction of
analgesic consumption. Pain assessment should ideally use self
reported scales such as the numeric rating scale (Chanques
et al., 2010), however, this can be limited by functional disability
from critical illness. It is imperative to ensure pain is evaluated
by an alternative method in the non-communicative patient
(Laycock and Bantel, 2016). Here, the ACCM recommend
using The Behavioral Pain Scale (BPS) or the Critical-Care
Pain Observation Tool (CPOT) (Barr et al., 2013; Devlin
et al., 2018). Whilst non-subjective measures of pain have
been developed which include new objective tools based on
physiological variables including electroencephalography, flexion
reflex, and pupillometry, their utility in the critically ill has
been conflicting. The analgesia nociceptive index, using heart
rate variability as response of the autonomic nervous system,
showed no correlation with BPS (Broucqsault-Dédrie et al.,
2016). Pupillometry was used for pain measurement during
endotracheal suctioning, but pupil size is influenced by multiple
factors which could confound the response (Paulus et al., 2013).
Nociception flexion reflex (NFR) threshold is based on scoring a
patient’s protective withdrawal reflex (Skljarevski and Ramadan,
2002) and although results correlate with self-reported pain, the
lack of a standardized scoring system limits its clinical application
(Cowen et al., 2015). A biological marker that measures the
genetic response through protein synthesis represents an ideal
objective method of measuring pain, however, nociception is
complex. It involves neuroendocrine and inflammation responses
which affect multiple systems. In this respect a combination of
several biological markers could represent the panacea of pain
assessment in the critically unwell (Cowen et al., 2015). Until
this is developed self report and behavioral tools mentioned are
the most evidence based methods to ensure targeting analgesia to
evaluate efficacy.
Pharmacological interventions
Pain should represent the principle tenant of analgosedation
management in critical care. Pain and discomfort is
recommended to be addressed prior to sedative use and
escalation. This approach has been shown to shorten length
of mechanical ventilation and ICU stay (Devabhakthuni et al.,
2012). Using the analogy with post-operative pain where
multimodal analgesia (MMA) is widely accepted, in the critically
ill patient this principle can provide an opioid sparing effect
and better quality of analgesia (Payen et al., 2013; Wick et al.,
2017). One of the rare studies investigating MMA in ICU, found
that MMA reduced doses of sedatives when used for baseline
pain management, procedural pain, pain related to disease, and
discomfort caused with mechanical ventilation (Payen et al.,
2013). The authors suggest that MMA concept can be applied to
a wider number of critically unwell patients not just for patients
with lower illness severity scores and ability to self rate their pain
intensity (Payen et al., 2013). However, its application can be
challenging in the critically unwell as multi organ insufficiency,
preexisting comorbidities and polypharmacy can hinder drug
choice and combinations. As physiologically unwell patients
present with variable pharmacodynamics and kinetics, frequency,
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severity and types of pain conditions, it is suggested that methods
of dosing medications should be individualized, as well as mode
of intravenous delivery (intermittent vs. continuous), and route
(oral, intravenous, or through the catheters for epidural or
regional blocks) (Barr et al., 2013).
Opioids. Intravenous opioids are the mainstay of treating
moderate to severe non-neuropathic pain in ICU (Barr
et al., 2013). However, their side effect profile includes
immunosuppression, hypotension, respiratory depression, chest
wall rigidity and gastro-enteric dysmotility (Devabhakthuni et al.,
2012). Some side effects can be dose dependent such chest
wall muscle rigidity. Choice of opioid remains controversial
as whilst remifentanil pharmacokinetic profile, with rapid
offset and minimal drug accumulation, has advantages over
fentanyl and morphine (Devabhakthuni et al., 2012), prolonged
use can lead to tolerance and opioid induced hyperalgesia
(Pandharipande and Ely, 2005).
A history of opioid use or misuse prior to critical care
admission presents a challenge. As with surgical patients on
chronic opioids, normal pre-admission opioid doses should be
continued as a baseline should the patients’ physiology allow
it. Additional short acting opioids, ideally as patient controlled
analgesia, can be used for additional pain needs alongside other
multimodal strategies. Where oral administration of medications
is not possible, pre-admission oral medications should be
changed to intravenous forms (Peng et al., 2005; Alford et al.,
2006; Mehta and Langford, 2006). Prior to ICU discharge, there
should be carefull tapering of opioids where appropriate to ensure
long term opioids are not continued unnecessarily leading to
chronic opioid use (Azzam and Alam, 2013). The aim should be
to return patients to at most the doses they were taking prior to
critical care admission. Iatrogenic withdrawal syndrome (IWS)
caused by abrupt tapering of opioids in adult ICU patients is
rarely explored in the literature. Small cohort studies recorded
IWS in 16–32% opioid treated adult ICU patients (Cammarano
et al., 1998; Wang P.P. et al., 2017). Wang P.P. et al. (2017)
identified risk factors including a higher cumulative opioid dose
and longer time of opioid use. There are no studies considering
how best to taper opioids in the critically ill adult. Consensus
guidelines from pediatric intensive care where tapering of opioids
and sedatives is common place, suggest no specific regimen,
however, one could consider reducing 5–10% of daily dose every
24 h (Playfor et al., 2006). Other potential options to reduce
the risk of IWS include the use of methadone, alpha-2 agonists
or NMDA receptor antagonists alone or in conjunction during
opioid reduction (Puntillo and Naidu, 2016).
Non-opioid analgesics. Non-opioid analgesics are recommended
for use in ICU to reduce or terminate use of opioids and therefore
reduce opioid side effects (Barr et al., 2013). Paracetamol and
non-steroidal anti-inflammatory drugs (NSAIDs) safety profile
and effectiveness are rarely and incompletely studied in critically
ill patients (Elia et al., 2005; Barr et al., 2013). NSAIDs inhibit
cyclooxygenase (COX) enzyme and this result in prostaglandin
production reduction. COX-2 inhibitors are developed for
selective inhibition of COX-2 enzyme isoform and show reduced
risk for gastric bleeding compared to NSAIDs. Both are associated
with numerous side effects, the most important of which in
the critically ill are risks associated with renal insufficiency,
cardiac failure and bleeding (Curtis et al., 2004). The antipyretic
and analgesic effects of paracetamol are in part explained by
selective COX inhibition within the central nervous system,
and also indirect effects via the vanilloid subtype one receptor
and cannabinoid type one receptors in the central nervous
system (Bertolini et al., 2006). Whilst concerns regarding hepatic
insufficiency and toxicity in the critically ill are likely minimal if
dosing is carefully considered, recent evidence regarding possible
hypotension caused by paracetamol and its risk in patients with
instability requires consideration prior to use (Weinberg et al.,
2015). There is a paucity of evidence regarding the role of
NSAIDs, COX-2 inhibitors and paracetamol, as part of MMA
regimen in critically ill patients, with focus on “clinically relevant”
dynamic pain intensity reduction, reduction of opioid side effects
and presence or absence of their own side effects (Elia et al.,
2005). Whilst literature from the post-operative pain setting
supports their inclusion especially as opioid sparing agents their
application in the ICU setting remains controversial and should
be considered on an individual patient basis (Remy et al., 2005;
Mcdaid et al., 2010; Jefferies et al., 2012; Barr et al., 2013).
Local anesthetics. Local anesthetics can be used in regional
anesthesia techniques or as an intravenous infusion (lidocaine).
Regional analgesia remains controversial in the critically ill. The
benefits include cardioprotective effects, especially from thoracic
epidural analgesia, reduced risk for deep venous thrombosis,
opioid sparing and improved analgesia that aids tracheal
extubation (Liu et al., 1995; Carrier et al., 2009; Bignami et al.,
2010; Horlocker et al., 2010; Caputo et al., 2011). Furthermore
catheter placement enables continuous peripheral nerve blockade
with local anesthetics in low concentrations (Williams et al.,
2003; Casati et al., 2007; Bernards et al., 2008). However, they
are not without risks which include infection and bleeding in
the presence of critical illness associated coagulopathy (Hebl,
2006; Hebl and Neal, 2006; Horlocker and Wedel, 2006; Wedel
and Horlocker, 2006; Horlocker et al., 2010). ACCM guidelines
recommend thoracic epidural anesthesia/analgesia consideration
for post-operative analgesia in patients undergoing abdominal
aortic aneurysm surgery and for patients with traumatic rib
fractures (Barr et al., 2013). However, due to lack of evidence no
recommendation was given for neuraxial/regional analgesia over
systemic analgesia in medical ICU patients (Barr et al., 2013).
Therefore regional analgesia application in the critically ill should
be individually evaluated.
There is no data regarding the use of intravenous lidocaine for
analgesia in critically ill patients. Perioperative intravenous
infusions of lidocaine are recommended for colorectal
surgery by the PROSPECT Working Group (2017). This
has been shown to reduce pain scores and post-operative
opioid consumption by 85% in various surgical procedures
and to reduce length of hospital stay (McCarthy et al.,
2010), however, more recent evaluation of the evidence is
less convincing (Kranke et al., 2015). Running lidocaine
intravenous infusions needs to be considered in light of
potential side effects pertinent in the critically unwell,
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including cardiac arrhythmia and accumulation secondary
to altered metabolism in those with heptic or renal failure
(Dickerson and Apfelbaum, 2014).
Co-analgesics. Ketamine is a non-competitive NMDA receptor
antagonist, with the potential to prevent central sensitization,
wind up phenomenon and opioid induced tolerance (Woolf
and Thompson, 1991; Mao et al., 1995). It is used to reduce
post-operative pain intensity, is opioid sparing (Laskowski
et al., 2011) and has demonstrated beneficial antidepressive
and neuroprotective effects (Hudetz and Pagel, 2010; Kishimoto
et al., 2016). Ketamine could be considered in pain refractory
to other therapies in the critically unwell (Patanwala et al.,
2017). However, there is also concern that extrapolating from
evidence in elderly post-operative patients where ketamine was
associated with negative experiences including hallucinations
and nightmares (Avidan et al., 2017), its influence on ICU
delirium requires attention prior to application. Additionally
its cardiovascular effects mean use should be considered on an
individual basis (Erstad and Patanwala, 2016).
Alpha-2 agonists provide analgesia, anxiolysis, have sedative
effects and do not cause respiratory depression (Chen et al.,
2015; Gagnon et al., 2015). Dexmedetomidine has been shown
to reduce the duration of mechanical ventilation and ICU
stay compared to “traditional sedatives” (Chen et al., 2015). It
can be used as a sole analgesic or with opioids in critically
ill patients (Shehabi et al., 2004). In experimental studies,
alpha-2 adrenergic agonists demonstrated antinociceptive effects
in visceral pain conditions (Ulger et al., 2009). Furthermore
dexmedetomidine has been shown to prolong the duration of
sensory block provided by local anesthetics during regional
analgesia (Akin et al., 2008; Kang et al., 2018). Its application
is promising although associated bradycardia and hypotension
need to be considered in the critically unwell (Devabhakthuni
et al., 2012). Clonidine, another alpha-2 agonist, represents
an alternative drug that again has demonstrated opioid-
sparing effects; however, it has cardiovascular effects including
hypotension and is reported to induce a withdrawal syndrome
(Wang J.G. et al., 2017). Its effect on sedation level in ICU
has been investigated with the conclusion that it can be an
effective and safe alternative to a dexmedetomidine infusion,
but its effect on CPIP prevention has not been considered
(Terry et al., 2015).
Gabapentinoids, gabapentin and pregabalin, are
anticonvulsants recommended for use in neuropathic pain
management (Finnerup et al., 2015). They share the main
mechanism of action, via α2-δ subunits of voltage-sensitive
calcium channels in presynaptic afferent neurons (Quintero,
2017). Gabapentoids can decrease analgesia requirements
and sedative medication use, but they are rarely investigated
in adult critically ill patients, despite the promising results
from pediatric ICU (Pandey et al., 2005; Sacha et al., 2017).
Beside sedation, dizziness, visual disturbances as adverse effects,
respiratory depression was described with gabapentin and opioid
combinations and concern is now present as they potentially
represent drugs of abuse (Cavalcante et al., 2017). Pregabalin can
cause confusion, somnolence, potentiate respiratory depression
of remifentanil and adverse effects on cognition and addiction
(Myhre et al., 2016; Bonnet and Scherbaum, 2017). Based on all
the above, and with no intravenous formulation, there is question
of clinical usefulness of gabapentoids in the critically unwell.
Certain antidepressants are effective in neuropathic pain
management, however, their ability to prevent developing
chronic pain states is unknown (Saarto and Wiffen, 2007).
Whilst amitriptyline and drugs such as duloxetine show
promise in chronic pain states, their application in critical care
has yet to be explored. Side effect profiles such as cardiac
effects of amitriptyline and drug interactions mean their use
in the critically unwell may be limited and lacks clinical
evidence. Serotonin-norepinephrine reuptake inhibitors (SNRI)
are recommended as first line treatment in neuropathic pain
(Finnerup et al., 2015). However, their effect on hemodynamics
and liver function limits their clinical usefulness in critically
unwell patients and they are not recommended for use in current
pain guidelines for critically unwell patients with neuropathic
pain (Devlin et al., 2018).
Other medications. Glucocorticosteroids mechanistically should
produce analgesia. They have multiple actions including
inhibition of prostaglandin synthesis, influence on activity and
plasticity of the nervous system and reduction of spontaneous
discharge in injured nerves (Watanabe and Bruera, 1994;
Mensah-Nyagan et al., 2009). Furthermore, endogenous
neurosteroids control various mechanisms involved in pain
sensation and modulate GABA, NMDA, and P2X receptors
(Mensah-Nyagan et al., 2009). However, glucocorticosteroids
have numerous side effects, and a case controlled study found
an increased rate of infection, increased ICU stay and increased
mechanical ventilation, with a trend toward increased mortality
in critically ill treated with steroids (Britt et al., 2006). Despite
studies in post-operative analgesia where dexamethasone
has been shown to reduce post-operative pain and opioid
consumption, there are no data available regarding the benefits
of glucocorticosteroid use as adjuvants for pain management in
critically ill patients (De Oliveira et al., 2011).
There is a relationship between sleep and both chronic
and acute pain (Finan et al., 2013). Disturbed and shortened
sleep has been shown experimentally in healthy volunteers to
cause hyperalgesia modification to pain perception and increase
reported pain intensity (Roehrs et al., 2006; Azevedo et al., 2011),
and the descending pain modulatory system is suggested as a
mediator for sleep disruption modulated hyperalgesia (Tiede
et al., 2010). ACCM recommends “promoting sleep in adult ICU
patients by optimizing patients’ environments, using strategies
to control light and noise, clustering patient care activities, and
decreasing stimuli at night to protect patients’ sleep cycles.”
Additionally the use of melatonin has been suggested in a recently
published summary of the Future of Critical Care Medicine
meeting (Barr et al., 2013; Marini et al., 2017). Individual
patient pharmacokinetics of melatonin are extremely variable,
and in critically unwell patients earlier peak, greater plasma
concentration and slower plasma clearance have been described
and therefore doses should be reduced to accomodate for this
(Bellapart and Boots, 2012). Additionally low clearance can
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lead to potentially “nocturnal” plasma levels during the late
morning that may nullify potential “chronotherapeutic” benefits
of melatonin (Arendt and Skene, 2005; Bourne et al., 2008).
It has been reported that to reach sufficient sleep length and
sleep quality, in some cases melatonin needs to be given for
up to 3 days, as a result of progressive melatonin sensitization
and an effect on timing mechanisms of sleep (Arendt et al.,
1984; Boyoko et al., 2012). The dose, formulation, timing of
administration, duration of melatonin treatment and assessment
of optimal circadian timing are still unclear in the critically unwell
(Arendt and Skene, 2005).
There is no evidence regarding the interaction between
sleep in ICU and either the experience of acute pain or the
development of CPIP, however, it is possible that addressing sleep
by prescribing melatonin, adjusting lights in order to imitate
day/night pattern, and providing windowed rooms can improve
circadian rhythm and sleep which in turn could influence pain
(Madrid-Navarro et al., 2015; Mo et al., 2016).
Non-pharmacological methods
Non-pharmacological methods used as part of MMA regimen
in the critically unwell might increase the effect of medications,
reduce opioid consumption and incidence of adverse drug events,
and reduce the need for opioids post-discharge.
Psychological support. Critical illness subjects patients to
psychological stress, anxiety, low mood, fear of dying and
hallucinations (Novaes et al., 1999; Jones et al., 2007; Wade
et al., 2013; Hadjibalassi et al., 2018). This can be attributed
to the experience of regular life disruption, the physical ICU
environment, an inability to communicate, and the effects
of critical illness and invasive treatments such as mechanical
ventilation. This can be associated with long term psychological
consequences including anxiety, depression, PTSD and chronic
fatigue syndrome (Griffiths et al., 2004). PTSD can accompany
chronic pain following critical illness, and whilst the exact
association is unknown, psychological interventions for PTSD
could impact on CPIP (Jenewein et al., 2009). It is important to
note PTSD interventions are most effective when implemented
early rather than post-discharge (Hatch et al., 2011; Wade
et al., 2013). This also emphasizes the importance of a clinical
psychologists being part of the ICU multidisciplinary team
(Hatch et al., 2011; Peris et al., 2011). It is also important to have
excellent communication between the multidisciplinary team, the
patient and their relatives (Meraner and Sperner-Unterweger,
2016). Nursing staff have an essential role in supporting
patients psychologically including explaining interventions and
establishing a relationship with both the patient and their family
(Pattison, 2005; Clancy et al., 2015; Marini, 2015).
Virtual reality. Virtual reality (VR) is computer-generated
simulation of a 3D image delivered with special equipment that
can interact with a patient’s pain by distraction (Hoffman et al.,
2011). It can have an opioid sparing effect and be associated with
pain reduction in burn patients, especially during wound care and
physical rehabilitation (Carrougher et al., 2009; McSherry et al.,
2018). In critically ill patients VR neurocognitive based therapy
improved attention and memory (Turon et al., 2017) and it has a
role in reducing opioid abuse in chronic pain patients and opioid
dependence in heroin addicts (Gupta et al., 2018). Certainly
VR looks promising as an additional strategy in managing pain
in ICU patients, however, further evidence including patient
selection and randomized controlled trials to evaluate effects of
VR on different types of procedural pain and overall pain states is
warranted (Hoffman et al., 2011; Indovina et al., 2018).
Music therapy. Music therapy is defined by the American Music
Therapy Association “as the clinical and evidence-based use of
music interventions to accomplish individualized goals within
a therapeutic relationship by a credentialed professional who
has completed an approved music therapy program” (American
Music Therapy Association [AMTA], 2011). Music is a cognitive
distractor (Chlan et al., 2013; Birnie et al., 2017), switching
attention via the thalamus to the prefrontal cortex rather than
painfull input and activating the endogenous opioid system to
modulate perception of pain (Economidou et al., 2012). Positive
effects of music therapy in ICU patients can be summarized as
anxiety reduction, improvement of blood pressure, heart, and
respiratory rate, quality of sleep and reduced pain intensity and
analgesics requirement (Bradt et al., 2013; Hole et al., 2015).
Meta analysis of 14 randomized trials focused on music therapy
effects in ICU patients on mechanical ventilation and showed
reduced anxiety, respiratory rate, systolic blood pressure and use
of sedation and analgesia medications (Bradt and Dileo, 2014).
Physiotherapy. Physiotherapy could prevent joint and limb pain,
particularly by reducing joint contractures, important in CPIP
(Clavet et al., 2008; Battle et al., 2013). Muscle atrophy and
weakness caused by prolonged bed rest during ICU treatment
can reduce patient mobility which persists up to 2 years after
discharge (Fan, 2012; Connolly et al., 2015). No data regarding
the influence of early physical therapy on CPIP are currently
available, however, this also warrants further investigation.
Post-discharge Period
Pain follow up clinic
Follow up to evaluate CPIP is important following ICU discharge.
This allows for evaluation of intensity and nature of continued
pain, to ensure appropriate analgesic prescribing and the
development of a long term plan for pain management. It is
likely this should occur within a specialized pain clinic that
would ensure psychological assistance. A neurorehabilitation
based protocol including use of patient diaries, focus groups with
other ICU survivors, cognitive and physical rehabilitation may
be useful to encorporate in such services (Clancy et al., 2015).
This comprehensive follow up in a dedicated service is essential
due to the significant number of patients that have pain despite
multimodal and multidisciplinary approaches to its management
(Lasiter et al., 2016; Hållstam et al., 2017).
FUTURE TRENDS
Genes code proteins with different roles, including receptors,
enzymes, proteins responsible for substance transfers and
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biometabolic mediators. Analysis of genetic polymorphism can
identify responders to particular medications and patients
response to treatment, providing personalized pain management
in the intensive care (Celi et al., 2013; Papaioannou et al.,
2014; Marini et al., 2015). In some critical illness states
molecular assays and gene mapping are already the reality
of treatment. As previously highlighted with respect to pain
assessment, however, it is likely that a panel of biomarkers is
more appropriate for evaluating pain, rather than one specific
biomarker (Bäckryd, 2015).
CONCLUSION
Modern pain management on ICU should not only address
acute pain, but also aim to prevent the development of CPIP
and ongoing opioid use. It’s management should involve a
protocolized approach that can be adjusted for each patient to
account for comorbidities and their presenting complaint. This
needs a systematic individualized multimodal pharmacological
and non-pharmacological treatment approach that utilizes a
multidisciplinary team. So far, no single medication or technique
has been proven as most effective in either acute management
within ICU or as a preventative measure for the development of
CPIP. However, strategies should include regular detailed pain
assessments using appropriate tools to evaluate initial pain and
response to treatment. Pharmacological strategies should involve
the lowest possible dose of opioids that is still effective, with the
aim of the earlist possible decline of the dose and slow transition
to non-opioid medications.
However, before individualized approaches can be fully
developed and evaluated there needs to be research that
leads to further understanding of risk factors for CPIP and
evaluate whether long term opioid use is prevalent in this
population. Answering these important questions could help
guide management to ensure the long term consequences of
either chronic pain or opioid dependence are not experienced in
the future by ICU patients.
AUTHOR CONTRIBUTIONS
DS initiated this report, designed the work, collected the data,
interpreted the data, and wrote the manuscript. HL designed the
work, collected the data, interpreted the data, wrote and revised
the manuscript. MK, NL, and VN contributed to literature search
and collected data. CB designed the work, collected the data,
interpreted the data, and revised the manuscript. All authors read
and approved the final manuscript.
FUNDING
This work was supported only for open access publication
fees from Carl von Ossietzky Universität Oldenburg,
Oldenburg, Germany.
REFERENCES
Akin, S., Aribogan, A., and Arslan, G. (2008). Dexmedetomidine as an adjunct to
epidural analgesia after abdominal surgery in elderly intensive care patients: a
prospective, double-blind, clinical trial. Curr. Ther. Res. 69, 16–28. doi: 10.1016/
j.curtheres.2008.02.001
Alford, D. P., Compton, P., and Samet, J. H. (2006). Acute pain management for
patients receiving maintenance methadone or buprenorphine therapy. Ann. Int.
Med. 144, 127–134. doi: 10.7326/0003-4819-144-2-200601170-00010
American Music Therapy Association [AMTA] (2011). Definition and Quotes
about Music Therapy. Available at: https://www.musictherapy.org/about/
quotes/.
American Psychiatric Association (2013). Diagnostic and Statistical Manual of
Mental Disorders, 5th Edn. Arlington, VA: American Psychiatric Publishing.
doi: 10.1176/appi.books.9780890425596
Arendt, J., Borbely, A. A., Franey, C., and Wright, J. (1984). The effects of chronic,
small doses of melatonin given in the late afternoon on fatigue in man: a
preliminary study. Neurosci. Lett. 45, 317–321. doi: 10.1016/0304-3940(84)
90245-3
Arendt, J., and Skene, D. J. (2005). Melatonin as a chronobiotic. Sleep Med. Rev. 9,
25–39. doi: 10.1016/j.smrv.2004.05.002
Avidan, M. S., Maybrier, H. R., Abdallah, A., Ben, Jacobsohn, E., Vlisides, P. E., et al.
(2017). Intraoperative ketamine for prevention of postoperative delirium or
pain after major surgery in older adults: an international, multicentre, double-
blind, randomised clinical trial. Lancet 390, 267–275. doi: 10.1016/S0140-
6736(17)31467-8
Azevedo, E., Manzano, G. M., Silva, A., Martins, R., Andersen, M. L., and Tufik, S.
(2011). The effects of total and REM sleep deprivation on laser-evoked potential
threshold and pain perception. Pain 152, 2052–2058. doi: 10.1016/j.pain.2011.
04.032
Azzam, P. N., and Alam, A. (2013). Pain in the ICU: a psychiatric perspective.
J. Intensive Care Med. 28, 140–150. doi: 10.1177/0885066611432417
Bäckryd, E. (2015). Pain in the blood? Envisioning mechanism-based diagnoses
and biomarkers in clinical pain medicine. Diagnostics 5, 84–95. doi: 10.3390/
diagnostics5010084
Ballantyne, J. C., and Mao, J. (2003). Opioid therapy for chronic pain. N. Engl. J.
Med. 349, 1943–1953. doi: 10.1056/NEJMra025411
Barr, J., Fraser, G. L., Puntillo, K., Ely, E. W., Gélinas, C., Dasta, J. F., et al.
(2013). Clinical practice guidelines for the management of pain, agitation, and
delirium in adult patients in the intensive care unit. Crit. Care Med. 41, 263–306.
doi: 10.1097/CCM.0b013e3182783b72
Battle, C. E., Lovett, S., and Hutchings, H. (2013). Chronic pain in survivors of
critical illness: a retrospective analysis of incidence and risk factors. Crit. Care
17:R101. doi: 10.1186/cc12746
Baumbach, P., Götz, T., Günther, A., Weiss, T., and Meissner, W. (2016).
Prevalence and characteristics of chronic intensive care-related pain: the role
of severe sepsis and septic shock. Crit. Care Med. 44, 1129–1137. doi: 10.1097/
CCM.0000000000001635
Bellapart, J., and Boots, R. (2012). Potential use of melatonin in sleep and delirium
in the critically ill. Br. J. Anaesth. 108, 572–580. doi: 10.1093/bja/aes035
Bernards, C., Hadzic, A., Suresh, S., and Neal, J. (2008). Regional anesthesia in
anesthetized or heavily sedated patients. Reg. Anesth. Pain Med. 33, 449–460.
doi: 10.1097/00115550-200809000-00008
Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., and Leone, S.
(2006). Paracetamol: new vistas of an old drug. CNS Drug Rev. 12, 250–275.
doi: 10.1111/j.1527-3458.2006.00250.x
Bignami, E., Landoni, G., Biondi-Zoccai, G. G. L., Boroli, F., Messina, M.,
Dedola, E., et al. (2010). Epidural analgesia improves outcome in
cardiac surgery: a meta-analysis of randomized controlled trials.
J. Cardiothorac. Vasc. Anesth. 24, 586–597. doi: 10.1053/j.jvca.2009.
09.015
Birnie, K. A., Chambers, C. T., and Spellman, C. M. (2017). Mechanisms of
distraction in acute pain perception and modulation. Pain 158, 1012–1013.
doi: 10.1097/j.pain.0000000000000913
Frontiers in Pharmacology | www.frontiersin.org 9 February 2019 | Volume 10 | Article 23
fphar-10-00023 February 20, 2019 Time: 17:18 # 10
Stamenkovic et al. Chronic Pain After ICU Discharge
Bonnet, U., and Scherbaum, N. (2017). How addictive are gabapentin and
pregabalin? A systematic review. Eur. Neuropsychopharmacol. 27, 1185–1215.
doi: 10.1016/j.euroneuro.2017.08.430
Bourne, R. S., Mills, G. H., and Minelli, C. (2008). Melatonin therapy to improve
nocturnal sleep in critically ill patients: encouraging results from a small
randomised controlled trial. Crit. Care 12, R52. doi: 10.1186/cc6871
Boyle, M., Murgo, M., Adamson, H., Gill, J., Elliott, D., and Crawford, M. (2004).
The effect of chronic pain on health related quality of life amongst intensive care
survivors. Aust. Crit. Care 17, 104–113. doi: 10.1016/S1036-7314(04)80012-2
Boyoko, Y., Ørding, H., and Jennum, P. (2012). Sleep disturbances in critically ill
patients in ICU: how much do we know? Acta Anaesthesiol. Scand. 56, 950–958.
doi: 10.1111/j.1399-6576.2012.02672.x
Bradt, J., and Dileo, C. (2014). Music interventions for mechanically ventilated
patients. Cochrane Database Syst. Rev. 12:CD006902. doi: 10.1002/14651858.
CD006902.pub3
Bradt, J., Dileo, C., and Potvin, N. (2013). Music for stress and anxiety reduction
in coronary heart disease patients. Cochrane Database Syst. Rev. 12:CD006577.
doi: 10.1002/14651858.CD006577.pub3
Britt, R. C., Devine, A., Swallen, K. C., Weireter, L. J., Collins, J. N., Cole, F. J., et al.
(2006). Corticosteroid use in the intensive care unit at what cost? Arch. Surg.
141, 145–149. doi: 10.1001/archsurg.141.2.145
Broucqsault-Dédrie, C., De Jonckheere, J., Jeanne, M., and Nseir, S. (2016).
Measurement of heart rate variability to assess pain in sedated critically
ill patients: a prospective observational study. PLoS One 11:e0147720.
doi: 10.1371/journal.pone.0147720
Cammarano, W. B., Pittet, J. F., Weitz, S., Schlobohm, R. M., and Marks, J. D.
(1998). Acute withdrawal syndrome related to the administration of analgesic
and sedative medications in adult intensive care unit patients. Crit. Care Med.
26, 676–684. doi: 10.1097/00003246-199804000-00015
Caputo, M., Alwair, H., Rogers, C. A., Pike, K., Cohen, A., Monk, C., et al. (2011).
Thoracic epidural anesthesia improves early outcomes in patients undergoing
off-pump coronary artery bypass surgery: a prospective, randomized, controlled
trial. Anesthesiology 114, 380–390. doi: 10.1097/ALN.0b013e318201f571
Carrier, F. M., Turgeon, A. F., Nicole, P. C., Trépanier, C. A., Fergusson, D. A.,
Thauvette, D., et al. (2009). Effect of epidural analgesia in patients with
traumatic rib fractures: a systematic review and meta-analysis of randomized
controlled trials. Can. J. Anaesth. 56, 230–242. doi: 10.1007/s12630-009-9052-7
Carrougher, G. J., Hoffman, H. G., Nakamura, D., Lezotte, D., Soltani, M., Leahy, L.,
et al. (2009). The effect of virtual reality on pain and range of motion in
adults with burn injuries. J. Burn Care Res. 30, 785–791. doi: 10.1097/BCR.
0b013e3181b485d3
Casati, A., Baciarello, M., Cianni, S., Di, Danelli, G., De Marco, G., et al. (2007).
Effects of ultrasound guidance on the minimum effective anaesthetic volume
required to block the femoral nerve. Br. J. Anaesth. 98, 823–827. doi: 10.1093/
bja/aem100
Cavalcante, A. N., Sprung, J., Schroeder, D. R., and Weingarten, T. N. (2017).
Multimodal analgesic therapy with gabapentin and its association with
postoperative respiratory depression. Anesth. Analg. 125, 141–146. doi: 10.1213/
ANE.0000000000001719
Celi, L. A., Mark, R. G., Stone, D. J., and Montgomery, R. A. (2013). “Big data” in
the intensive care unit. Closing the data loop. Am. J. Respir. Crit. Care Med. 187,
1157–1160. doi: 10.1164/rccm.201212-2311ED
Chanques, G., Viel, E., Constantin, J.-M., Jung, B., de Lattre, S., Carr, J., et al. (2010).
The measurement of pain in intensive care unit: comparison of 5 self-report
intensity scales. Pain 151, 711–721. doi: 10.1016/j.pain.2010.08.039
Chen, K., Lu, Z., Xin, Y. C., Cai, Y., Chen, Y., and Pan, S. M. (2015). Alpha-
2 agonists for long-term sedation during mechanical ventilation in critically
ill patients. Cochrane Database Syst. Rev. 1:CD010269. doi: 10.1002/14651858.
CD010269.pub2
Chlan, L. L., Weinert, C. R., Heiderscheit, A., Tracy, M. F., Skaar, D. J., Guttormson,
J. L., et al. (2013). Effects of patient-directed music intervention on anxiety
and sedative exposure in critically ill patients receiving mechanical ventilatory
support: a randomized clinical trial. JAMA 309, 2335–2344. doi: 10.1001/jama.
2013.5670
Choi, J., Hoffman, L. A., Schulz, R., Tate, J., Donahoe, M. P., Ren, D., et al. (2014).
Self reported physical symptoms in intensive care unit (ICU) survivors: pilot
exploration over four months post ICU discharge. J. Pain Symptom Manage. 47,
257–270. doi: 10.1016/j.jpainsymman.2013.03.019
Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., Davies, P.,
et al. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic
noncancer pain. J. Pain 10, 113–130. doi: 10.1016/j.jpain.2008.10.008
Clancy, O., Edginton, T., Casarin, A., and Vizcaychipi, M. P. (2015). The
psychological and neurocognitive consequences of critical illness. A pragmatic
review of current evidence. J. Intensive Care Soc. 16, 226–233. doi: 10.1177/
1751143715569637
Clavet, H., Hebert, P. C., Fergusson, D., Doucette, S., and Trudel, G. (2008). Joint
contracture following prolonged stay in the intensive care unit. CMAJ 178,
691–697. doi: 10.1503/cmaj.071056
Connolly, B., Salisbury, L., O’Neill, B., Geneen, L., Douiri, A., Grocott, M. P. W.,
et al. (2015). Exercise rehabilitation following intensive care unit discharge
for recovery from critical illness. Cochrane Database Syst. Rev. 6:CD008632.
doi: 10.1002/14651858.CD008632.pub2
Cowen, R., Stasiowska, M. K. K., Laycock, H., and Bantel, C. (2015). Assessing
pain objectively: the use of physiological markers. Anaesthesia 70, 828–847.
doi: 10.1111/anae.13018
Curtis, S. P., Ng, J., Yu, Q., Shingo, S., Bergman, G., McCormick, C. L., et al. (2004).
Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory
drugs in controlled clinical trials. Clin. Ther. 26, 70–83. doi: 10.1016/S0149-
2918(04)90007-0
De Oliveira, G. S., Almeida, M. D., Benzon, H. T., and McCarthy, R. J. (2011).
Perioperative single dose systemic dexamethasone for postoperative pain: a
meta-analysis of randomized controlled trials. Anesthesiology 115, 575–588.
doi: 10.1097/ALN.0b013e31822a24c2
Devabhakthuni, S., Armahizer, M. J., Dasta, J. F., and Kane-Gill, S. L. (2012).
Analgosedation: a paradigm shift in intensive care unit sedation practice. Ann.
Pharmacother. 46, 530–540. doi: 10.1345/aph.1Q525
Devlin, J. W., Skrobik, Y., Gélinas, C., Needham, D. M., Slooter, A. J. C.,
Pandharipande, P. P., et al. (2018). Clinical practice guidelines for the
prevention and management of pain, agitation/sedation, delirium, immobility,
and sleep disruption in adult patients in the ICU. Crit. Care Med. 46, 825–873.
doi: 10.1097/CCM.0000000000003299
Dickerson, D. M., and Apfelbaum, J. L. (2014). Local anesthetic systemic toxicity.
Aesthetic Surg. J. 34, 1111–1119. doi: 10.1177/1090820X14543102
Economidou, E., Klimi, A., Vivilaki, V. G., and Lykeridou, K. (2012). Does music
reduce postoperative pain? A review. Health Sci. J. 6, 365–377.
Elia, N., Lysakowski, C., and Tramèr, M. R. (2005). Does multimodal analgesia
with acetaminophen, nonsteroidal antiinflammatory drugs, or selective
cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer
advantages over morphine alone? Meta-analyses of randomized trials.
Anesthesiology 103, 1296–1304. doi: 10.1097/00000542-200512000-00025
Ely, E. W. (2017). The ABCDEF bundle: science and philosophy of how
ICU liberation serves patients and families. Crit. Care Med. 45, 321–330.
doi: 10.1097/CCM.0000000000002175
Erstad, B. L., and Patanwala, A. E. (2016). Ketamine for analgosedation in critically
ill patients. J. Crit. Care 35, 145–149. doi: 10.1016/j.jcrc.2016.05.016
Fan, E. (2012). Critical illness neuromyopathy and the role of physical therapy and
rehabilitation in critically Ill patients. Respir. Care 57, 933–946. doi: 10.4187/
respcare.01634
Finan, P. H., Goodin, B. R., and Smith, M. T. (2013). The association of sleep and
pain: an update and a path forward. J. Pain 14, 1539–1552. doi: 10.1016/j.jpain.
2013.08.007
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin,
R. H., et al. (2015). Pharmacotherapy for neuropathic pain in adults: a
systematic review and meta-analysis. Lancet Neurol. 14, 162–173. doi: 10.1016/
S1474-4422(14)70251-0
Fletcher, D., Stamer, U. M., Pogatzki-Zahn, E., Zaslansky, R., Tanase, N. V.,
Perruchoud, C., et al. (2015). Chronic postsurgical pain in Europe: an
observational study. Eur. J. Anaesthesiol. 32, 725–734. doi: 10.1097/EJA.
0000000000000319
Gagnon, D. J., Riker, R. R., Glisic, E. K., Kelner, A., Perrey, H. M., and Fraser,
G. L. (2015). Transition from dexmedetomidine to enteral clonidine for
ICU sedation: an observational pilot study. Pharmacotherapy 35, 251–259.
doi: 10.1002/phar.1559
Granja, C., Teixeira-Pinto, A., and Costa-Pereira, A. (2002). Quality of life after
intensive care – Evaluation with EQ-5D questionnaire. Intensive Care Med. 28,
898–907. doi: 10.1007/s00134-002-1345-z
Frontiers in Pharmacology | www.frontiersin.org 10 February 2019 | Volume 10 | Article 23
fphar-10-00023 February 20, 2019 Time: 17:18 # 11
Stamenkovic et al. Chronic Pain After ICU Discharge
Griffiths, J., Hatch, R. A., Bishop, J., Morgan, K., Jenkinson, C., Cuthbertson, B. H.,
et al. (2013). An exploration of social and economic outcome and associated
health-related quality of life after critical illness in general intensive care unit
survivors: a 12-month follow-up study. Crit. Care 17, R100. doi: 10.1186/
cc12745
Griffiths, J. A., Gager, M., and Waldmann, C. (2004). Follow-up after intensive
care. Contin Educ. Anaesth. Crit. Care Pain 4, 202–205. doi: 10.1093/bjaceaccp/
mkh054
Gupta, A., Scott, K., and Dukewich, M. (2018). Innovative technology using virtual
reality in the treatment of pain: does it reduce pain via distraction, or is there
more to it? Pain Med. 19, 151–159. doi: 10.1093/pm/pnx109
Hadjibalassi, M., Lambrinou, E., Papastavrou, E., and Papathanassoglou, E. (2018).
The effect of guided imagery on physiological and psychological outcomes
of adult ICU patients: a systematic literature review and methodological
implications. Aust. Crit. Care 31, 73–86. doi: 10.1016/j.aucc.2017.03.001
Hållstam, A., Löfgren, M., Benson, L., Svensén, C., and Stålnacke, B. M. (2017).
Assessment and treatment at a pain clinic: a one-year follow-up of patients with
chronic pain. Scand. J. Pain 17, 233–242. doi: 10.1016/j.sjpain.2016.08.004
Hatch, R., McKechnie, S., and Griffiths, J. (2011). Psychological intervention to
prevent ICU-related PTSD: who, when and for how long? Crit. Care 15:141.
doi: 10.1186/cc10054
Hebl, J., and Neal, J. (2006). Infectious complications: a new practice advisory. Reg.
Anesth. Pain Med. 31, 289–290. doi: 10.1016/j.rapm.2006.05.001
Hebl, J. R. (2006). The importance and implications of aseptic techniques
during regional anesthesia. Reg. Anesth. Pain Med. 31, 311–323. doi: 10.1097/
00115550-200607000-00006
Herridge, M. S., Cheung, A. M., Tansey, C. M., Matte-Martyn, A., Diaz-
Granados, N., Al-Saidi, F., et al. (2003). One-year outcomes in survivors
of the acute respiratory distress syndrome. N. Engl. J. Med. 348, 683–693.
doi: 10.1056/NEJMoa022450
Herridge, M. S., Tansey, C. M., Matte, A., Tomlinson, G., Diaz-Granados, N.,
Cooper, A. B., et al. (2011). Functional disability 5 years after acute
respiratory distress sydnrome. N. Engl. J. Med. 364, 1293–1304. doi: 10.1056/
NEJMoa1011802
Hoffman, H. G., Chambers, G. T., Meyer, W. J., Arceneaux, L. L., Russell, W. J.,
Seibel, E. J., et al. (2011). Virtual reality as an adjunctive non-pharmacologic
analgesic for acute burn pain during medical procedures. Ann. Behav. Med. 41,
183–191. doi: 10.1007/s12160-010-9248-7
Hole, J., Hirsch, M., Ball, E., and Meads, C. (2015). Music as an aid for postoperative
recovery in adults: a systematic review and meta-analysis. Lancet 386,
1659–1671. doi: 10.1016/S0140-6736(15)60169-6
Horlocker, T., and Wedel, D. (2006). Regional anesthesia in the
immunocompromised patient. Reg. Anesth. Pain Med. 31, 334–345.
doi: 10.1097/00115550-200607000-00008
Horlocker, T. T., Wedel, D. J., Rowlingson, J. C., Enneking, F. K., Kopp,
S. L., Benzon, H. T., et al. (2010). Regional anesthesia in the patient
receiving antithrombotic or thrombolytic therapy: american society of regional
anesthesia and pain medicine evidence-based guidelines (third edition). Reg.
Anesth. Pain Med. 35, 64–101. doi: 10.1097/AAP.0b013e3181c15c70
Hudetz, J. A., and Pagel, P. S. (2010). Neuroprotection by ketamine: a review of the
experimental and clinical evidence. J. Cardiothorac. Vasc. Anesth. 24, 131–142.
doi: 10.1053/j.jvca.2009.05.008
Indovina, P., Barone, D., Gallo, L., Chirico, A., De Pietro, G., and Antonio, G.
(2018). Virtual reality as a distraction intervention to relieve pain and distress
during medical procedures: a comprehensive literature review. Clin. J. Pain 34,
858–877. doi: 10.1097/AJP.0000000000000599
Jefferies, S., Saxena, M., and Young, P. (2012). Paracetamol in critical illness: a
review. Crit. Care Resusc. 14, 74–80.
Jenewein, J., Moergeli, H., Wittmann, L., Büchi, S., Kraemer, B., and Schnyder, U.
(2009). Development of chronic pain following severe accidental injury. Results
of a 3-year follow-up study. J. Psychosom. Res. 66, 119–126. doi: 10.1016/j.
jpsychores.2008.07.011
Jones, C., Bäckman, C., Capuzzo, M., Flaatten, H., Rylander, C., and Griffiths,
R. D. (2007). Precipitants of post-traumatic stress disorder following intensive
care: a hypothesis generating study of diversity in care. Intensive Care Med. 33,
978–985. doi: 10.1007/s00134-007-0600-8
Kang, R., Jeong, J. S., Yoo, J. C., Lee, J. H., Choi, S. J., Gwak, M. S., et al.
(2018). Effective dose of intravenous dexmedetomidine to prolong the analgesic
duration of interscalene brachial plexus block: a single-center, prospective,
double-blind, randomized controlled trial. Reg. Anesth. Pain Med. 43, 488–495.
doi: 10.1097/AAP.0000000000000773
Katz, J., Rosenbloom, B. N., and Fashler, S. (2015). Chronic pain, psychopathology,
and DSM-5 somatic symptom disorder. Can. J. Psychiatry 60, 160–167.
doi: 10.1177/070674371506000402
Kemp, H. I., Bantel, C., Gordon, F., Brett, S. J., Laycock, H. C., et al. (2017). Pain
assessment in INTensive care (PAINT): an observational study of physician-
documented pain assessment in 45 intensive care units in the United Kingdom.
Anaesthesia 72, 1–12. doi: 10.1111/anae.13786
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., et al.
(2016). Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate
receptor antagonists for unipolar and bipolar depression: a meta-analysis of
efficacy, safety and time trajectories. Psychol. Med. 46, 1459–1472. doi: 10.1017/
S0033291716000064
Korošec Jagodicˇ, H., Jagodicˇ, K., and Podbregar, M. (2006). Long-term outcome
and quality of life of patients treated in surgical intensive care: a comparison
between sepsis and trauma. Crit. Care 10, 1–7.
Kranke, P., Jokinen, J., Pace, N. L., Schnabel, A., Hollmann, M. W.,
Hahnenkamp, K., et al. (2015). Continuous intravenous perioperative lidocaine
infusion for postoperative pain and recovery. Cochrane Database Syst. Rev.
7:CD009642. doi: 10.1002/14651858.CD009642.pub2
Lasiter, S., Oles, S. K., Mundell, J., London, S., and Khan, B. (2016). Critical care
follow-up clinics: a scoping review of interventions and outcomes. Clin. Nurse
Spec. 30, 227–237. doi: 10.1097/NUR.0000000000000219
Laskowski, K., Stirling, A., McKay, W. P., and Lim, H. J. (2011). A systematic
review of intravenous ketamine for postoperative analgesia. Can. J. Anesth. 58,
911–923. doi: 10.1007/s12630-011-9560-0
Laycock, H., and Bantel, C. (2016). Objective assessment of acute pain. J. Anesth.
Clin. Res. 7:6. doi: 10.4172/2155-6148.1000630
Liu, S., Carpenter, R. L., and Neal, J. M. (1995). Epidural anesthesia and
analgesia. Their role in postoperative outcome. Anesthesiology 82, 1474–1506.
doi: 10.1097/00000542-199506000-00019
Madrid-Navarro, C. J., Sanchez-Galvez, R., Martinez-Nicolas, A., Marina, R.,
Garcia, J. A., Madrid, J. A., et al. (2015). Disruption of circadian rhythms
and delirium, sleep impairment and sepsis in critically ill patients. potential
therapeutic implications for increased light-dark contrast and melatonin
therapy in an ICU environment. Curr. Pharm. Des. 21, 3453–3468. doi: 10.2174/
1381612821666150706105602
Mao, J., Price, D. D., and Mayer, D. J. (1995). Mechanisms of hyperalgesia and
morphine tolerance: a current view of their possible interactions. Pain 62,
259–274. doi: 10.1016/0304-3959(95)00073-2
Marini, J. J. (2015). Re-tooling critical care to become a better intensivist:
something old and something new. Crit. Care 19, S3. doi: 10.1186/cc14721
Marini, J. J., De Backer, D., Ince, C., Singer, M., Van Haren, F., Westphal, M., et al.
(2017). Seven unconfirmed ideas to improve future ICU practice. Crit. Care
21:315. doi: 10.1186/s13054-017-1904-x
Marini, J. J., Vincent, J.-L., and Annane, D. (2015). Critical care evidence—New
directions. JAMA 313:893. doi: 10.1001/jama.2014.18484
McCarthy, G. C., Megalla, S. A., and Habib, A. S. (2010). Impact of intravenous
lidocaine infusion on postoperative analgesia and recovery from surgery:
a systematic review of randomized controlled trials. Drugs 70, 1149–1163.
doi: 10.2165/10898560-000000000-00000
Mcdaid, C., Maund, E., Rice, S., Wright, K., Jenkins, B., and Woolacott, N.
(2010). Health technology assessment NIHR HTA programme paracetamol and
selective and non-selective non-steroidal anti- inflammatory drugs (NSAIDs)
for the reduction of morphine-related side effects after major surgery: a
systematic review. Health Technol. Assess. (Rockv) 14, 17. doi: 10.3310/hta14170
McSherry, T., Atterbury, M., Gartner, S., Helmold, E., Searles, D. M., and
Schulman, C. (2018). Randomized, crossover study of immersive virtual reality
to decrease opioid use during painful wound care procedures in adults. J. Burn
Care Res. 39, 278–285.
Mehta, V., and Langford, R. M. (2006). Acute pain management for opioid
dependent patients. Anaesthesia 61, 269–276. doi: 10.1111/j.1365-2044.2005.
04503.x
Mensah-Nyagan, A. G., Meyer, L., Schaeffer, V., Kibaly, C., and Patte-Mensah, C.
(2009). Evidence for a key role of steroids in the modulation of pain.
Psychoneuroendocrinology 34, S169–S177. doi: 10.1016/j.psyneuen.2009.06.004
Frontiers in Pharmacology | www.frontiersin.org 11 February 2019 | Volume 10 | Article 23
fphar-10-00023 February 20, 2019 Time: 17:18 # 12
Stamenkovic et al. Chronic Pain After ICU Discharge
Meraner, V., and Sperner-Unterweger, B. (2016). [Patients, physicians and nursing
personnel in intensive care units: psychological and psychotherapeutic
interventions]. Nervenarzt 87, 264–268. doi: 10.1007/s00115-016-
0098-9
Mo, Y., Scheer, C. E., and Abdallah, G. T. (2016). Emerging role of melatonin and
melatonin receptor agonists in sleep and delirium in intensive care unit patients.
J. Intensive Care Med. 31, 451–455. doi: 10.1177/0885066615592348
Myhre, M., Diep, L. M., and Stubhaug, A. (2016). Pregabalin has analgesic,
ventilatory, and cognitive effects in combination with remifentanil.
Anesthesiology 124, 141–149. doi: 10.1097/ALN.0000000000000913
Needham, D. M., Davidson, J., Cohen, H., Hopkins, R. O., Weinert, C., Wunsch, H.,
et al. (2012). Improving long-term outcomes after discharge from intensive
care unit: report from a stakeholders’ conference. Crit. Care Med. 40, 502–509.
doi: 10.1097/CCM.0b013e318232da75
Novaes, M. A., Knobel, E., Bork, A. M., Pavão, O. F., Nogueira-Martins, L. A.,
and Ferraz, M. B. (1999). Stressors in ICU: perception of the patient, relatives
and health care team. Intensive Care Med. 25, 1421–1426. doi: 10.1007/
s001340051091
Pandey, C. K., Raza, M., Tripathi, M., Navkar, D. V., Kumar, A., and Singh, U. K.
(2005). The comparative evaluation of gabapentin and carbamazepine for pain
management in Guillain-Barré syndrome patients in the intensive care unit.
Anesth. Analg. 101, 220–225. doi: 10.1213/01.ANE.0000152186.89020.36
Pandharipande, P., and Ely, E. W. (2005). Narcotic-based sedation regimens for
critically ill mechanically ventilated patients. Crit. Care 9:247. doi: 10.1186/
cc3523
Papaioannou, V., Mebazaa, A., Plaud, B., and Legrand, M. (2014). “Chronomics”
in ICU: circadian aspects of immune response and therapeutic perspectives in
the critically ill. Intensive Care Med. Exp. 2:18. doi: 10.1186/2197-425X-2-18
Patanwala, A. E., Martin, J. R., and Erstad, B. L. (2017). Ketamine for
analgosedation in the intensive care unit: a systematic review. J. Intensive Care
Med. 32, 387–395. doi: 10.1177/0885066615620592
Pattison, N. (2005). Psychological implications of admission to critical care. Br. J.
Nurs. 14, 708–714. doi: 10.12968/bjon.2005.14.13.18452
Paulus, J., Roquilly, A., Beloeil, H., Théraud, J., Asehnoune, K., and Lejus, C.
(2013). Pupillary reflex measurement predicts insufficient analgesia before
endotracheal suctioning in critically ill patients. Crit. Care 17, R161.
doi: 10.1186/cc12840
Payen, J.-F., Bosson, J.-L., Chanques, G., Mantz, J., Labarere, J., and Dolorea
Investigators. (2009). Pain assessment is associated with decreased duration
of mechanical ventilation in the intensive care unit: a post Hoc analysis
of the DOLOREA study. Anesthesiology 111, 1308–1316. doi: 10.1097/ALN.
0b013e3181c0d4f0
Payen, J.-F., Genty, C., Mimoz, O., Mantz, J., Bosson, J.-L., and Chanques, G.
(2013). Prescribing nonopioids in mechanically ventilated critically ill patients.
J. Crit. Care 28, 7–534. doi: 10.1016/j.jcrc.2012.10.006
Peng, P. W. H., Tumber, P. S., and Gourlay, D. (2005). Review article: perioperative
pain management of patients on methadone therapy. Can. J. Anesth. 52,
513–523. doi: 10.1007/BF03016532
Peris, A., Bonizzoli, M., Iozzelli, D., Migliaccio, M. L., Zagli, G., Bacchereti, A.,
et al. (2011). Early intra-intensive care unit psychological intervention
promotes recovery from post traumatic stress disorders, anxiety and depression
symptoms in critically ill patients. Crit. Care 15:R41. doi: 10.1186/cc
10003
Playfor, S., Jenkins, I., Boyles, C., Choonara, I., Davies, G., Haywood, T., et al.
(2006). Consensus guidelines on sedation and analgesia in critically ill children.
Intensive Care Med. 32, 1125–1136. doi: 10.1007/s00134-006-0190-x
PROSPECT Working Group (2017). Open Colonic Resection – Specific Evidence –
Lidocaine. Available at: https://www.postoppain.org/sections/?root_id=62933&
section=13
Puntillo, K. A., and Naidu, R. (2016). Chronic pain disorders after critical illness
and ICU-acquired opioid dependence. Curr. Opin. Crit. Care 22, 506–512.
doi: 10.1097/MCC.0000000000000343
Quintero, G. C. (2017). Review about gabapentin misuse, interactions,
contraindications and side effects. J. Exp. Pharmacol. 9, 13–21.
doi: 10.2147/JEP.S124391
Remy, C., Marret, E., and Bonnet, F. (2005). Effects of acetaminophen on morphine
side-effects and consumption after major surgery: meta-analysis of randomized
controlled trials. Br. J. Anaesth. 94, 505–513. doi: 10.1093/bja/aei085
Roehrs, T., Hyde, M., Blaisdell, B., Greenwald, M., and Roth, T. (2006). Sleep loss
and REM sleep loss are hyperalgesic. Sleep 29, 145–151. doi: 10.1093/sleep/29.
2.145
Saarto, T., and Wiffen, P. J. (2007). Antidepressants for neuropathic pain. Cochrane
Database Syst. Rev. 4:CD005454. doi: 10.1002/14651858.CD005454.pub2
Sacha, G. L., Foreman, M. G., Kyllonen, K., and Rodriguez, R. J. (2017). The use
of gabapentin for pain and agitation in neonates and infants in a neonatal ICU.
J. Pediatr. Pharmacol. Ther. 22, 207–211. doi: 10.5863/1551-6776-22.3.207
Shehabi, Y., Ruettimann, U., Adamson, H., Innes, R., and Ickeringill, M. (2004).
Dexmedetomidine infusion for more than 24 hours in critically ill patients:
sedative and cardiovascular effects. Intensive Care Med. 30, 2188–2196.
doi: 10.1007/s00134-004-2417-z
Skljarevski, V., and Ramadan, N. M. (2002). The nociceptive flexion reflex in
humans – Review article. Pain 96, 3–8. doi: 10.1016/S0304-3959(02)00018-0
Skrobik, Y., Ahern, S., Leblanc, M., Marquis, F., Awissi, D. K., and Kavanagh, B. P.
(2010). Protocolized intensive care unit management of analgesia, sedation, and
delirium improves analgesia and subsyndromal delirium rates. Anesth. Analg.
111, 451–463. doi: 10.1213/ANE.0b013e3181d7e1b8
Sukantarat, K., Greer, S., Brett, S., and Williamson, R. (2007). Physical and
psychological sequelae of critical illness. Br. J. Health Psychol. 12, 65–74.
doi: 10.1348/135910706X94096
Terry, K., Blum, R., and Szumita, P. (2015). Evaluating the transition from
dexmedetomidine to clonidine for agitation management in the intensive care
unit. SAGE Open Med. 3:2050312115621767. doi: 10.1177/2050312115621767
Tiede, W., Magerl, W., Baumgärtner, U., Durrer, B., Ehlert, U., and Treede, R.-D.
(2010). Sleep restriction attenuates amplitudes and attentional modulation of
pain-related evoked potentials, but augments pain ratings in healthy volunteers.
Pain 148, 36–42. doi: 10.1016/j.pain.2009.08.029
Timmers, T. K., Verhofstad, M. H. J., Moons, K. G. M., van Beeck, E. F., and
Leenen, L. P. H. (2011). Long-term quality of life after surgical intensive care
admission. Arch. Surg. 146:412. doi: 10.1001/archsurg.2010.279
Treede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., et al.
(2015). A classification of chronic pain for ICD-11. Pain 156, 1003–1007. doi:
10.1097/j.pain.0000000000000160
Turon, M., Fernandez-Gonzalo, S., Jodar, M., Gomà, G., Montanya, J.,
Hernando, D., et al. (2017). Feasibility and safety of virtual-reality-based early
neurocognitive stimulation in critically ill patients. Ann. Intensive Care 7:81.
doi: 10.1186/s13613-017-0303-4
Ulger, F., Bozkurt, A., Bilge, S. S., Ilkaya, F., Dilek, A., Bostanci, M. O., et al. (2009).
The antinociceptive effects of intravenous dexmedetomidine in colorectal
distension-induced visceral pain in rats: the role of opioid receptors. Anesth.
Analg. 109, 616–622. doi: 10.1213/ane.0b013e3181a9fae2
Von Korff, M., Korff, M., Von, Saunders, K., Thomas Ray, G., Boudreau, D., et al.
(2008). De facto long-term opioid therapy for noncancer pain. Clin. J. Pain 24,
521–527. doi: 10.1097/AJP.0b013e318169d03b
Wade, D., Hardy, R., Howell, D., and Mythen, M. (2013). Identifying clinical and
acute psychological risk factors for PTSD after critical care: a systematic review.
Minerva Anestesiol. 79, 944–963.
Wang, J. G., Belley-Coté, E., Burry, L., Duffett, M., Karachi, T., Perri, D., et al.
(2017). Clonidine for sedation in the critically ill: a systematic review and
meta-analysis. Crit. Care 21:75. doi: 10.1186/s13054-017-1610-8
Wang, P. P., Huang, E., Feng, X., Bray, C.-A., Perreault, M. M., Rico, P., et al.
(2017). Opioid-associated iatrogenic withdrawal in critically ill adult patients:
a multicenter prospective observational study. Ann. Intensive Care 7:88.
doi: 10.1186/s13613-017-0310-5
Watanabe, S., and Bruera, E. (1994). Corticosteroids as adjuvant analgesics. J. Pain
Symptom Manage. 9, 442–445. doi: 10.1016/0885-3924(94)90200-3
Wedel, D., and Horlocker, T. (2006). Regional anesthesia in the febrile or
infected patient. Reg. Anesth. Pain Med. 31, 324–333. doi: 10.1097/00115550-
200607000-00007
Weinberg, A. L., Chiam, E., Weinberg, L., and Bellomo, R. (2015). Paracetamol:
a review with specific focus on the haemodynamic effects of intravenous
administration. Heart Lung Vessel 7, 121–132.
Wick, E. C., Grant, M. C., and Wu, C. L. (2017). Postoperative multimodal
analgesia pain management with nonopioid analgesics and techniques. JAMA
Surg. 152:691. doi: 10.1001/jamasurg.2017.0898
Williams, S. R., Chouinard, P., Arcand, G., Harris, P., Ruel, M., Boudreault, D.,
et al. (2003). Ultrasound guidance speeds execution and improves the quality
Frontiers in Pharmacology | www.frontiersin.org 12 February 2019 | Volume 10 | Article 23
fphar-10-00023 February 20, 2019 Time: 17:18 # 13
Stamenkovic et al. Chronic Pain After ICU Discharge
of supraclavicular block. Anesth. Analg. 97, 1518–1523. doi: 10.1213/01.ANE.
0000086730.09173.CA
Woolf, C. J., and Thompson, S. W. (1991). The induction and maintenance
of central sensitization is dependent on N-methyl-D-aspartic acid
receptor activation; implications for the treatment of post-injury pain
hypersensitivity states. Pain 44, 293–299. doi: 10.1016/0304-3959(91)
90100-C
Yaffe, P. B., Green, R. S., Butler, M. B., and Witter, T. (2017). Is admission to
the intensive care unit associated with chronic opioid use? A 4-year follow-
up of intensive care unit survivors. J. Intensive Care Med. 32, 429–435.
doi: 10.1177/0885066615618189
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Stamenkovic, Laycock, Karanikolas, Ladjevic, Neskovic and
Bantel. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 13 February 2019 | Volume 10 | Article 23
